Player FM 앱으로 오프라인으로 전환하세요!
PT538 – Rumination, the Default Mode Network, and How Neuroplasticity Changes Over Time, with Dr. Jerry Rosenbaum & Sharmin Ghaznavi, MD, Ph.D.
Manage episode 434019420 series 1088550
In this episode, Chris Koddermann interviews two members of the Center for the Neuroscience of Psychedelics at Mass General Hospital: founding director, author, and co-founder of three drug development companies, Dr. Jerry Rosenbaum; and psychiatrist and associate director and director of cognitive neuroscience, Sharmin Ghaznavi, MD, Ph.D.
Rosenbaum and Ghaznavi bonded over an interest in rumination, and wondered: How could the plasticity-inducing effects of psychedelics change these negative loops people find themselves in? How important is the ability to break out of those loops – and learn new patterns – when our concept of self is so central to who we are? Ghaznavi is studying the effects of psilocybin on rumination and scanning patients at multiple times throughout the process to track data we still don’t really have: how psychedelic-induced neuroplasticity changes over time, and why.
They discuss:
- How much of a role the default mode network takes in the therapeutic benefits of psychedelics: Is it overblown?
- Hyperscanning, which involves scanning two individuals at the same time, looking for potential concordance in signal and/or an increased alliance between the therapist and patient
- The Schultes Legacy Project and the work of Stephen Haggarty to explore the potential of largely unstudied psychoactive plants
- Critiques of the recent ruling on Lykos and MDMA-assisted therapy and the clash between the FDA and the advisory committee: Were they really on the same page?
- The false dichotomy of neuroscience vs. patient experience: Does the subjective experience actually increase plasticity and other measurable benefits?
and more!
670 에피소드
Manage episode 434019420 series 1088550
In this episode, Chris Koddermann interviews two members of the Center for the Neuroscience of Psychedelics at Mass General Hospital: founding director, author, and co-founder of three drug development companies, Dr. Jerry Rosenbaum; and psychiatrist and associate director and director of cognitive neuroscience, Sharmin Ghaznavi, MD, Ph.D.
Rosenbaum and Ghaznavi bonded over an interest in rumination, and wondered: How could the plasticity-inducing effects of psychedelics change these negative loops people find themselves in? How important is the ability to break out of those loops – and learn new patterns – when our concept of self is so central to who we are? Ghaznavi is studying the effects of psilocybin on rumination and scanning patients at multiple times throughout the process to track data we still don’t really have: how psychedelic-induced neuroplasticity changes over time, and why.
They discuss:
- How much of a role the default mode network takes in the therapeutic benefits of psychedelics: Is it overblown?
- Hyperscanning, which involves scanning two individuals at the same time, looking for potential concordance in signal and/or an increased alliance between the therapist and patient
- The Schultes Legacy Project and the work of Stephen Haggarty to explore the potential of largely unstudied psychoactive plants
- Critiques of the recent ruling on Lykos and MDMA-assisted therapy and the clash between the FDA and the advisory committee: Were they really on the same page?
- The false dichotomy of neuroscience vs. patient experience: Does the subjective experience actually increase plasticity and other measurable benefits?
and more!
670 에피소드
Semua episode
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.